Articles tagged with Chagas Disease
A UTEP team has made significant progress in developing a human vaccine for cutaneous leishmaniasis, a tropical disease affecting thousands worldwide. Their research results in a 96% decrease in lesions and an 86% protection rate from the disease in mice.
Research has found that most Central American 'kissing bugs' infect people with just two strains of the Chagas disease parasite, TcI and TcIV. The study identified a high level of genetic variation within these strains, which may impact vaccine development and treatment.
Researchers used computational drug discovery and in vitro enzyme assays to identify potential therapeutic protein inhibitors for Chagas disease. The study successfully selected four drug-like compounds that interacted with a key amino acid, demonstrating the promise of docking simulation for identifying effective treatments.
Researchers have identified new hosts for Chagas Disease vectors, including tayras, monkeys, sloths, porcupines, and coatis, using DNA analysis. This discovery increases knowledge of Chagas disease transmission in rural environments and will support efforts to control the disease, particularly in poor, rural populations in South America.
Researchers at UTEP have been awarded a patent for a potential vaccine against Chagas disease, a life-threatening tropical illness. The vaccine, which has shown promising results in non-human primates, could provide a much-needed solution to the growing number of people infected with the disease.
A new study published in PLOS Neglected Tropical Diseases found that Chagas disease significantly increases the risk of death, especially among those with cardiac complications. The study suggests that deaths from Chagas have been under-reported due to misdiagnosis and highlights the need for further research into new therapeutic options.
A new intervention developed by Bar-Ilan University scientists can control parasite migration by creating an unfavorable environment or damaging cell health. This research has the potential to lead to the development of drugs to treat and prevent diseases such as African sleeping sickness, leishmaniasis, and Chagas' disease.
Researchers have identified multiple targets for Chagas disease chemotherapy, including ergosterol biosynthesis pathway and cruzipain, a key cysteine protease. Novel synthesized anti-T.cruzi compounds with specific single or multi-target assigned have also been described, highlighting potential for effective treatment.
A study published in PLOS Neglected Diseases reveals that Chagas disease has a significant presence in the Rio Grande Valley of Texas, affecting up to 30% of those infected with Trypanosoma cruzi developing fatal cardiomyopathy. The research estimates 4,600 people are currently infected and 1,300 at risk for cardiac disease.
Researchers found resveratrol reversed mouse heart dysfunction by improving pumping efficiency and reducing oxidative damage. The study suggests potential for resveratrol and similar substances to treat Chagas cardiomyopathy in humans.
Scientists at MIT and the University of São Paulo have identified the structure of an enzyme that targets parasites responsible for spreading these diseases. The distinctive structure of the class I fumarate hydratase enzyme makes it a promising target for new medical therapies.
Scientists have made a breakthrough in understanding the parasites that cause Chagas disease, leishmaniasis, and human African trypanosomiasis, three neglected diseases affecting 20 million people worldwide. A new chemical has been developed to kill these parasites, offering hope for effective treatments.
Scientists have identified a single compound that can kill parasites responsible for three neglected diseases: Chagas disease, leishmaniasis and sleeping sickness. The new study suggests a single class of drugs could be used to treat all three diseases.
FeverPhone is a smartphone-based diagnostic system that can diagnose six febrile diseases in the field using a drop of blood, providing rapid and accurate diagnoses. The system has the potential to improve healthcare outcomes in resource-limited countries by enabling timely treatment and reducing morbidity and mortality.
Researchers developed stealth nanocapsules that cure more than half of infected mice with Chagas disease, outperforming conventional nanocapsules. The new delivery system is simple to produce and can be taken orally, making it a practical solution for treating the disease in less developed countries.
The BENEFIT trial suggests that treating Chagas disease earlier is crucial, as it did not show incremental benefits in cardiac outcome. The study found that 17-18% of patients died over a period of five years, with the number comparable to breast cancer mortality.
Two vector-borne diseases, Chagas' disease and Leishmaniasis, can be transmitted from mother to child through the placenta, posing a significant risk to newborns. Research highlights the importance of healthcare workers remembering these diseases when examining sick children whose mothers have traveled from affected areas.
The study reveals a low prevalence of T. cruzi parasites with limited genetic diversity, contradicting previous assumptions about the parasite's presence in the US. This suggests that local transmission of Chagas disease may be lower than previously thought, but also highlights the need for increased awareness and diagnosis.
Chagas disease is a life-threatening illness caused by the protozoan Trypanosoma cruzi. In Spain, Latin American migrants are at high risk due to mother-to-child transmission, with an estimated 50,000-70,000 people infected. Screening is crucial to detect heart abnormalities early and prevent sudden cardiac death.
Researchers identify unique expansions of gene families related to chemoreception and feeding in Rhodnius prolixus, the kissing bug that transmits Chagas disease. These findings may lead to novel approaches for controlling or eliminating the disease by targeting specific genes or processes.
Research found that carbohydrate-binding protein Gal-1 modified infection in heart muscle cells, highlighting its importance in response to parasite infection. Galectins, like Gal-1, play a role in regulating parasite interactions and may recognize glycans on the host cell surface used for invasion.
A UTHealth researcher has received a $544,329 CDC grant to develop region-specific educational materials and implement outreach on Chagas disease in South Texas. Approximately 20-30% of infected persons will enter the chronic phase, which can manifest as heart disease or gastrointestinal issues.
A study by University of Texas at El Paso researchers found that 61% of kissing bugs in west Texas are infected with the Trypanosoma cruzi parasite, which causes Chagas disease. The disease can lead to life-threatening symptoms like heart rhythm abnormalities and difficult eating or passing stool.
Researchers found that injecting specific adult fat tissue cells early after Chagas Disease infection can modify the animal's response, reducing parasite presence and heart inflammation. The study aims to explore the use of these cells as a potential treatment for cardiac damage caused by the disease.
Researchers will evaluate existing Cathepsin S inhibitor as new potential Chagas disease therapeutic, addressing a neglected tropical disease with no FDA-approved therapies. The grant aims to confirm the antiparasitic activity and test safety and effectiveness in humans.
Researchers at UTMB have successfully tested a vaccine for Chagas disease, which can provide long-lasting immunity in animal models. The vaccine was found to significantly reduce parasite levels and prevent chronic symptoms, making it a promising tool for control of this infection.
Researchers found that bed bugs can acquire and transmit the parasite Trypanosoma cruzi, causing Chagas disease. The study demonstrated bi-directional transmission of the parasite between mice and bed bugs, highlighting a potential emerging problem.
Researchers found high rates of individuals testing positive for Chagas disease and related heart disease in Texas, with rates 50 times higher than CDC estimates. The study aims to increase awareness and diagnosis of this emerging infectious disease in the southern United States.
A Phase II trial is being conducted to test fexinidazole, a 'rediscovered' drug, for its safety and efficacy in treating Chagas disease. The study aims to determine if the drug is safer and more effective than placebo in clearing the parasite that causes the disease.
The study found evidence of severe Chagas disease and suggests that the young Incan girl may have been victim of ritual homicide. The analysis of her mummy revealed massive skull and face trauma, indicating a pre-mortem injury, which is similar to previously described South American mummies.
Researchers have developed two compounds that disrupt an enzyme used by the parasite causing Chagas disease, showing greater cure rates than existing treatments. The new compounds have significant potential as a safe and effective treatment for this life-threatening illness.
A Phase 2 clinical trial in Bolivia found that experimental drug candidate E1224 showed good safety and efficacy in clearing the Chagas parasite, but had little sustained efficacy as a single medication. Standard therapy benznidazole was effective but associated with side effects.
Researchers say Chagas disease remains a leading cause of heart disease in impoverished North American communities, with inadequate healthcare and limited treatment options available. The editorial calls for increased medical awareness, scientific cooperation, and public-private partnerships to develop new tools and treatments.
Researchers at Vanderbilt University Medical Center have discovered a potential cure for both acute and chronic forms of Chagas disease in mice using the small molecule VNI. The treatment achieved 100% survival without toxic side effects.
Chagas disease infects an estimated 10 million people worldwide, causing significant economic burden, including USD $6.7 billion in future healthcare costs in the United States.
DNDi will receive a $17.3 million grant from UNITAID to accelerate the development and delivery of child-adapted antiretroviral therapy (ARV) formulations for babies and toddlers with HIV/AIDS, including those co-infected with tuberculosis. This support aims to improve treatment accessibility and outcomes for young children affected by...
A new $3 million study will investigate biological markers measuring treatment efficacy for Chagas disease. The research seeks to develop a robust test to expand treatment options and accelerate clinical trials for this potentially fatal neglected tropical disease.
Researchers found that 38% of kissing bugs in Arizona and California contained human blood, carrying the parasite that causes Chagas disease. The study raises awareness about the potential for transmission in the US, where the disease is currently rare.
The Drugs for Neglected Diseases Initiative (DNDi) has received a €2 million Strategic Translation Award from the Wellcome Trust to develop E1224, a pro-drug with potent in vivo and in vitro activity against T. cruzi, the parasite causing Chagas disease.
Key findings: DNDi highlights the need for enhanced research and development for new treatment and diagnostic tools for NTDs. The organization stresses that filling R&D gaps is crucial to achieving disease control or elimination by 2020.
Epidemiological maps suggest South Texas is an area of high risk for Chagas infection, with potentially hundreds of undiagnosed cases. The disease can be hard to detect and may be misinterpreted as a flu-like illness, leading to delayed diagnosis.
A team of researchers, led by Michael Levy, have traced the spread of Chagas disease in Peru using advanced mathematical methods and door-to-door surveys. They found that the parasite was introduced into the region around 20 years ago, with most infections occurring over the last decade.
The Drugs for Neglected Diseases Initiative (DNDi) has launched a new research project to develop a macrofilaricidal drug candidate, flubendazole, to treat co-infection of filarial diseases. The project aims to assess the safety profile and reformulate the drug to reduce treatment cycles from 12 years to 2-3 years.
Scientists demonstrate a novel mechanism for Chagas disease's devastating effects: a parasite-driven autoimmune response that alters host genome. This chicken model reveals the origin of Chagas-like heart disease in the absence of parasitism, shedding new light on this lethal endemic infectious disease.
Chagas disease affects 10-12 million people in Latin America, killing 15,000 annually. Dogs can spread the disease and may help control it by acting as sentinels for health officials.
A Ph.D. student has received a fellowship to study the enzyme UDP-galactopyranose mutase, which produces a sugar absent in humans, offering a potential target for drug treatment. The research aims to understand the chemical mechanism and develop new treatments for Chagas' disease.
Scientists aim to prevent insects from spreading deadly diseases like Chagas' by manipulating physiology to stop the transmission of the illness. Researchers have identified genes controlling diuresis in kissing bugs and hope to create a peptide agonist to prevent waste and parasites from being left on wounds.
A team of researchers from McGill/MUHC has developed a novel screening tool to diagnose Chagas disease, a parasitic disease affecting over 10 million people in the Americas. The new approach uses mass spectrometry technology to identify specific biological markers left by the parasite, enabling rapid and reliable diagnosis.
Chagas disease is a neglected cause of stroke, with nearly a third of patients developing severe heart problems. Screening for Trypanosoma cruzi infection and long-term oral anticoagulants may help prevent stroke recurrence.
Researchers found that tall palm trees with debris should be targeted for Chagas disease surveillance and control. They suggest simple environmental management practices like removing organic debris can reduce the risk of vector-human contact.
A study published in PLOS Neglected Tropical Diseases suggests that frequent seasonal moves by shantytown residents to rural valleys with Chagas vectors are a key contributor to the growing presence of Chagas disease near urban Arequipa, Peru. The researchers propose three key interventions to improve control of Chagas disease in urban...
Researchers at Tufts University have discovered how the parasite Trypanosoma cruzi prolongs its life in human host cells by activating anti-apoptotic molecules, enabling it to evade death. This study provides new insights into the mechanisms behind Chagas' disease.
Researchers have developed a low-cost strategy to discover new drugs for neglected diseases, utilizing global educational resources and distributed problem-solving. Students worldwide are synthesizing candidate molecules, meeting industry standards, and participating in the process.
Researchers have discovered a cryptic species of kissing bugs that co-exist with known carrier species of the Chagas disease-causing parasite, despite being genetically distinct. The study's findings suggest that understanding what keeps these species separated is crucial to developing effective control measures.
A comprehensive survey of global spending on neglected disease R&D found that just over $2.5 billion was invested in 2007, with HIV/AIDS, TB, and malaria receiving nearly 80% of the total funding. Many neglected diseases are underfunded, with some receiving less than 4% of global funding.
Dr. David M. Engman, a renowned expert in Chagas disease research, has been awarded the prestigious ASIP-AMGEN Outstanding Investigative Award. His work focuses on understanding the mechanisms of Chagas disease and creating animal models to develop new treatments.
Researchers at the University of Georgia have developed a sensitive method to test and assess drug treatments for Chagas disease. The study found that the current drug therapies can only cure the infection in less than 50% of those treated, but also identified a potential new treatment approach.
A new screening strategy has been developed to detect Chagas disease in children, which could lead to improved diagnosis and treatment in low-resource settings. The strategy uses data from insecticide spraying campaigns to target diagnostic testing, identifying over 83% of infected children.
Researchers have identified a novel pathway in Trypanosoma brucei parasites that can be triggered to shut down the synthesis of a crucial RNA molecule, leading to parasite death. This discovery has implications for eradicating other parasitic diseases such as Leishmania and Chagas disease.
Researchers discovered the first human case of insect-transmitted Chagas parasite in Louisiana, with over half of collected insects carrying the parasite. The finding, while significant, does not represent a widespread public health concern due to limited rural housing conditions.